SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 29.81-4.2%Dec 5 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LarryS who wrote (8297)1/15/1999 10:23:00 AM
From: aknahow   of 17367
 
Larry, see you on Yahoo so this partial quote from slgonzalez is probably not new to you.

"With total mortality being critical
by: slgonzalez
4727 of 4727
...to the design and power of the investigation, the total mortality number must be met for the proper
focus to statistically capture the Neuprex story in meningococcemia. It is optimistic, IMO, that that
number forcasted by the stats folks has not been met by the total number of patients studied thus far.
Seems likely that there is something more than rapid diagnosis and optimal treatment going on, i.e.
maybe a (very) high survival rate in the treatment arm? As if life or death is not enough, there are other
endpoints besides and beyond this whole discussion."

Me again, not Gonzalea!

I am absolutly delighted with this as I share the thoughts of Gonzalez. She has certainly explained the situation much more clearly than I could have done.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext